Janssen, GSK China HIV Approvals Show Increased Transparency
This article was originally published in PharmAsia News
Executive Summary
In a rare move and a further indication of a determination to break away from its past, the China FDA has made timely public announcements of the approval of two new treatments for HIV that it deems to be breakthroughs, although it could be some time before they reach the market.
You may also be interested in...
China Poised To Conditionally Approve First COVID Vaccine
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Innovation-Friendly? Cases Indicate How Far China's Willing To Protect Patents
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
Rapid Response, No Ultracold: China Sees Global Opening For Vaccine Supplies
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.
Need a specific report? 1000+ reports available
Buy Reports